# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has res...
Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognit...
On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in p...
Rodman & Renshaw analyst Elemer Piros reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $67 price target.
Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson'...
This patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3032752-92-1), which has dem...